Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A five-year effort by Penn’s Abramson Cancer Center increased clinical trial enrollment of Black patients with cancer from 12% to 24%.
New targeted therapies and immunotherapies can lead to better treatment outcomes.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
Cancer Health blogger Dann Wonser says the key to his 14-year survival with non-small-cell lung cancer is his wife, Genevieve de Renne.
Effort aims to help dying patients gain legal access to psilocybin — the mind-altering compound found in so-called magic mushrooms.
After being diagnosed with internal melanoma, Gail decided to undergo a clinical trial of an experimental combination.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.